BACKGROUND The CoreValve U.S. Pivotal High Risk Trial was the first randomized trial to show superior 1-year mortality of transcatheter aortic valve replacement (TAVR) compared with surgical aortic valve replacement (SAVR) among high operative mortality-risk patients.
T ranscatheter aortic valve replacement (TAVR) is now a recognized alternative to surgical aortic valve replacement (SAVR) with 1-to 3-year mortality and stroke outcomes that are equivalent.
Specifically, the PARTNER IA (Placement of AoRTic TraNscathetER Valve Trial) with a balloon-expandable annular valve showed TAVR to be noninferior to SAVR in high-risk patients in the short and mid term (1, 2) .
Congruously, the CoreValve U.S. Pivotal High Risk Trial with a self-expanding supraannular valve showed TAVR to be superior to SAVR for the primary endpoint of allcause mortality at 1 (3) and 2 (4) years with a numerical, but not statistical, advantage remaining at 3 years (5) . These trials have resulted in a Class I, Level of Evidence: A recommendation for patients with symptomatic severe aortic stenosis (AS) and high surgical mortality risk to undergo either TAVR or SAVR (6) . We now report the final 5-year outcomes for high-risk patients in this trial. (3, 9) . Surgical valve selection was left to the operator's discretion. Echocardiographic data presented are site-reported. All patients with a presumed neurological event were seen by a neurologist, and appropriate imaging was obtained. All neurological events were adjudicated by a neurologist from the clinical events committee. Clinical outcomes and hemodynamic assessments at 5 years were pre-specified. 
METHODS

STATISTICAL
RESULTS
PATIENTS.
A total of 995 patients were screened for the trial, of whom 795 were enrolled and 750 There were no statistical differences in all-cause mortality at 5 years between TAVR and SAVR across 9 subgroups; age over 85 years, sex, body mass index, STS PROM score, left ventricular ejection fraction, hypertension, prior coronary artery bypass grafting, peripheral vascular disease, or diabetes mellitus (Online Figure 1 ). Landmarked analysis of all-cause mortality also showed no difference between TAVR and SAVR out to 5 years (p ¼ 0.64) (Online Figure 2 p < 0.001) by 5 years post-procedure ( Table 1) .
There were no differences in 5 years, there were no differences in the rate of any stroke for TAVR and SAVR (17.5% vs. 21.0%, respectively; p ¼ 0.13) or major stroke (12.3% vs. 13.2%, respectively; p ¼ 0.49) ( Table 1 ). The rate of transient ischemic attacks also did not differ between groups.
Similar to the mortality outcomes, the 5-year stroke rates specifically for iliofemoral access patients were Gleason et al. Health Survey (Online Figure 4) .
HEMODYNAMICS AND SVD. Serial echocardiograms through 5 years showed TAVR to be superior to SAVR for effective orifice area and mean gradient at all time points ( Figure 3) while being inferior for total AR (Figure 4) , which was primarily due to PVL. Mild and TAVR in Patients at Increased Surgical Risk greater AR at 1 month assessed by the echocardiographic core laboratory was associated with an increased all-cause and cardiovascular mortality at 5 years ( Figure 5A) . Considering the composite of cardiovascular mortality or reintervention ( Figure 5B) , the moderate/severe group had the greatest incidence of reintervention. There were no patients that developed severe AR, and 6 TAVR and no SAVR patients had moderate AR.
The overall incidence of SVD and components of moderate and severe SVD are shown in Table 3 .
Severe SVD was observed in 3 patients (0.8%) in the TAVR group and 6 patients (1.7%) in the SAVR group This is the first randomized trial to our knowledge to report mid-term 5-year hemodynamic outcomes with this self-expanding valve in high-risk patients compared with surgery. Long-term durability has been a major concern for all biological replacement valves. Durability has historically been defined as survival without the need for reoperation (10) . However, more recent guidelines suggest that SVD should be defined by clinically determined measures rather than reoperation or echo criteria alone, suggesting the need for reoperation (11) . Using the recent definitions by Capodanno et al. (8) from the European cardiovascular community, the incidence of severe SVD was rare and similar between treatment groups.
Moderate SVD was more common in the SAVR versus the TAVR patients (26.6% vs. 9.2%; p < 0.001), although much of this difference was attributable to higher gradients seen in certain SAVR patients that Transcatheter valve replacement was associated with significantly larger effective orifice area, and significantly smaller mean gradients at each time point compared with surgery (all p < 0.01). AVG ¼ aortic valve gradient; EOA ¼ effective orifice area; other abbreviations as in Figure 1 .
Gleason et al. Table 1) .
The incidence of clinically significant (mild or more) AR was higher in TAVR than SAVR in this trial, consistent with rates seen in other randomized trials (2, 3, 21, 22) . Cardiovascular mortality was higher for patients with mild AR at 1 month but, surprisingly, not for none/trace or moderate/severe ( Figure 5A) . The lack of apparent impact on mortality for moderate AR in this current trial may be a result of the low incidence of moderate AR seen and thus a consequence of a type II statistical error. The composite of cardiovascular death or reintervention showed that the patients with moderate/severe AR early on, had a higher incidence of interventions, while there was negligible effect on the other AR groups by adding the intervention procedures ( Figure 5B ). More TAVR than SAVR patients were implanted with a permanent pacemaker over the 5 years (33.0% vs. 19.8%), yet this did not appear to increase mortality at least out to 5 years.
Since the completion of the trial both second- Gleason et al. Values are % (n/N).
SVD ¼ structural valve deterioration; other abbreviations as in Tables 1 and 2 . TAVR in Patients at Increased Surgical Risk
